-
<![CDATA[Monitoring and Managing Adverse Events in Hemophilia Prophylaxis]]>
04 Feb 2026 15:34 GMT
Effective hemophilia management requires vigilant monitoring for … of life for people with hemophilia.
-
<![CDATA[Real-World Insights and Monitoring of Non-Factor Therapies in Hemophilia]]>
04 Feb 2026 15:34 GMT
… , provides valuable guidance for optimizing hemophilia management. Clinicians may consider switching … personalized care for people with hemophilia.
-
Federal Funding Bill Commits $3 Million To Versiti Blood Research Institute Expansion
05 Feb 2026 04:17 GMT
… United States facing blood cancers, hemophilia, sickle cell disease, and countless … new hope to patients with hemophilia A.
The 79,000-square …
-
Novo Nordisk slumps on tougher 2026 financial outlook
04 Feb 2026 19:54 GMT
… CagriSema (cagrilintide and semaglutide) and haemophilia therapy Mim8, as well as …
-
Pfizer Inc. (NYSE:PFE) Q4 2025 Earnings Call Transcript
04 Feb 2026 13:09 GMT
… aged six to 11 in hemophilia B with or without inhibitor … support more patients living with hemophilia.
Our third strategic priority is …
-
Pharmaceuticals Market to Register a Robust CAGR of 8.19% During the 2026–2034 Forecast Period
04 Feb 2026 13:00 GMT
… HYMPAVZI for the treatment of hemophilia A and B.
• May 2024 …
-
Ozempic Maker Novo Nordisk Flags Declining Sales In 2026
04 Feb 2026 12:31 GMT
… treatments, such as Mim8 within haemophilia and CagriSema within obesity, as …
-
Israeli‑led research could end insulin shots
04 Feb 2026 10:42 GMT
… to chronic conditions such as hemophilia and other metabolic or genetic …
-
2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now?
04 Feb 2026 08:45 GMT
… more resources to drive the hemophilia A candidate MGX-001 forward …
-
Viral Vector Manufacturing Market to Reach US$8.0 Bn by 2032 | Persistence Market Research
04 Feb 2026 07:13 GMT
… (SMA), inherited retinal dystrophy, and hemophilia B. Companies are heavily investing …